

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**Novel polyhydroxyalkanoate bead-based vaccines against
Pseudomonas aeruginosa infection**

A thesis presented in partial fulfilment of the
requirements for the degree of

Master of Science
In
Biological Sciences

at Massey University, Palmerston North,
New Zealand

Zennia Jean Gonzaga
2018

Abstract

Pseudomonas aeruginosa infections are increasingly problematic due to their multiple antibiotic resistances. To date, there is no commercial vaccine against *P. aeruginosa* infection. This study used polyhydroxyalkanoate (PHA) beads as a delivery platform for selected *P. aeruginosa* antigens to produce novel particulate vaccines against *P. aeruginosa*. Genetic engineering was used to modify the PHA synthase (PhaC), the enzyme that catalyses PHA bead formation, to produce functionalised PHA beads displaying the antigens. The highly conserved PopB antigen, recently revealed as an effective stimulator of Th17 immunity was displayed on the bead surface together with and without the previously selected antigens Ag (epitopes derived from outer membrane proteins OprI, OprF and AlgE). The PHA beads were produced in two production strains: (1) the pathogen *P. aeruginosa* itself, with the benefit of co-purifying host cell proteins (HCPs) expanding the antigen repertoire that could boost the immune response, and (2) *E. coli* strain ClearColi™, a defined mutant incapable of lipopolysaccharide synthesis enabling production of endotoxin free PHA beads. Vaccination of mice with antigen-coated PHA beads (only PopB or with additional Ag) showed increased production of IL-17, a reflection of induction of a Th17 immunity. Furthermore, Th1 and Th2 mediated immunity were detected from the IgG analysis of the immunised mice with the PHA bead vaccines. Significant enhancement of Th1 immune response using the PHA bead platform was observed compared to the antigen-only counterparts. Challenge of immunised mice with pathogenic *P. aeruginosa* showed that PopB-displaying PHA beads from *P. aeruginosa* and Ag-displaying PHA beads from *E. coli* induced partially protective immunity. The promising PHA bead candidate vaccines can be conjugated with other antigens such as the exopolysaccharide Psl for induction of improved immune response towards protective immunity.

Exopolysaccharide Psl is a mannose rich polymer produced by *P. aeruginosa* in both mucoid and nonmucoid phenotypes. Psl has been revealed to play an essential role in *P. aeruginosa* pathogenicity such as biofilm formation. Previous studies had provided evidence that CdrA binds directly to Psl, functioning as a Psl cross-linker and possibly tethering Psl to the cell surface. Psl is commercially not available, hence the aim of this study was to develop a Psl production strain. This study created a *cdrA* knockout mutant that produces free Psl which may be a potential vaccine antigen against *P.*

aeruginosa infections. An isogenic knockout of *cdrA* was obtained by homologous recombination and this mutant overproduced Psl released from the cell surface. In future studies, this strain will be used to produce Psl to serve as antigen in vaccine formulations.

Acknowledgements

“Success is not final, failure is not fatal: it is the courage to continue that counts”.

-Winston Churchill-

This milestone of my career would not have been possible without the help of many people. I would like to thank my supervisor, Professor Bernd Rehm for the opportunity to work under his supervision, and for his unending guidance and encouragement. I am grateful to my co-supervisor, Dr. Zoe Jordens for all of her help, her very useful comments and feedback, and her patience in editing my thesis. I appreciate the help of Jason Lee, Yajie Wang and Jinping Du for guiding me with my experiments. I would also like to thank all my colleagues at Rehm’s laboratory, Shuxiong, Majela, Jin, Kampachiro, First, Jason Smith, Patri, Shirin and Fata for the great camaraderie and advice.

I would like to thank New Zealand Aid Scholarship for funding my postgraduate study and the International Student Support team who are very accommodating and helpful throughout my entire stay. My research would have not been possible without the funding provided by Massey University and the MacDiarmid Institute for Advanced Materials and Nanotechnology. My thanks also to the Harvard medical group in the United States for conducting the animal trials and providing me with the data of the immunological analysis and bacterial challenge experiments.

I would like to extend my gratitude to all of my professors, friends, classmates and everyone that has been a part of my New Zealand journey. You have reinforced my interest in biological science at the molecular level and made being away from home significantly easier.

Special thanks to my very optimistic and loving big buddy, Rich Marks for all the support and motivating me when I needed it, as well as to the other buddies. To my family, Nanay, Tatay and Joan for the love and care that they have and are giving me every step of the way. Above all, the almighty God.

Table of Contents

Abstract	i
Acknowledgements	iii
Table of Contents	iv
List of Abbreviations	viii
List of Figures	xi
List of Tables	xiv
Chapter 1: Introduction	1
1.1 Polyhydroxyalkanoate	2
1.2 PHA synthase	4
1.3 Formation of PHA beads	6
1.3.1 Biosynthesis of PHA beads.....	6
1.3.2 Self-assembly mechanisms of PHA beads.....	8
1.4 Immobilization of proteins on PHA beads	9
1.4.1 Applications of PHA beads as bio-beads.....	10
1.5 <i>Pseudomonas aeruginosa</i> as a pathogen	12
1.5.1 Antibiotic resistance of <i>P. aeruginosa</i>	13
1.5.2 Vaccine development.....	13
1.5.2.1 Traditional vaccines.....	13
1.5.2.2 Modern vaccines.....	14
1.5.2.3 PHA beads as vaccines and their production hosts.....	16
1.5.3 Potential antigens for protection against <i>P. aeruginosa</i>	17
1.6 Host immune response to <i>P. aeruginosa</i>	22
1.7 Aim and objectives of this study	24
Chapter 2: Materials and Methods	30
2.1 Bacterial strains, plasmids and primers	30
2.2 Media	39
2.2.1 Liquid media.....	39
2.2.2 Solid media.....	41
2.3 Antibiotic stock solutions and concentrations	41
2.4 Cultivation conditions	42
2.4.1 PHA formation conditions.....	42
2.4.2 Protein production conditions.....	44

2.5 Long-term storage and revival of bacterial strains	45
2.6 Competent cell preparation and plasmid DNA uptake	45
2.6.1 Preparation and transformation of competent <i>E. coli</i>	45
2.6.2 Preparation and electroporation of electro-competent <i>P. aeruginosa</i> ...	46
2.6.3 Transconjugation of <i>P. aeruginosa</i>	47
2.7 Molecular cloning	48
2.7.1 Plasmid isolation and concentration.....	48
2.7.2 DNA Hydrolysis with restriction endonucleases.....	49
2.7.3 Polymerase chain reaction	49
2.7.4 Agarose gel electrophoresis	51
2.7.4.1 DNA ladder standards.....	52
2.7.5 Recovery of DNA fragment from agarose gels.....	53
2.7.6 DNA ligation.....	53
2.7.7 DNA sequencing.....	53
2.8 PHA bead and protein isolation	54
2.8.1 Cell harvesting.....	54
2.8.2 Cell disruption.....	55
2.8.2.1 Sonicator.....	55
2.8.2.2 Microfluidizer.....	55
2.8.3 PHA bead purification and sterilization	56
2.8.4 Protein purification and sterilization.....	57
2.9 Characterisation of PHA beads	58
2.9.1 Nile-red staining and Fluorescent microscopy.....	58
2.9.2 Gas chromatography-mass spectrometry.....	59
2.9.3 Transmission Electron Microscopy	60
2.10 General methods of protein analysis	60
2.10.1 Sodium dodecyl polyacrylamide gel electrophoresis.....	60
2.10.2 Densitometry.....	64
2.10.3 Immunoblot analysis.....	64
2.10.4 Mass spectrometry (MS).....	65
2.11 Animal testing of the PHA beads and immunological analyses	65
2.11.1 Mice vaccination.....	66
2.11.2 Immunological assays.....	66
2.11.3 Challenge with <i>P. aeruginosa</i> N13 strain.....	66

2.11.4 Statistical analysis.....	67
2.12 Assessment of the <i>cdrA</i> knockout mutant.....	67
2.12.1 Solid surface attachment assay.....	67
2.12.2 Enzyme-linked immunosorbent assay.....	67
Chapter 3: Results.....	69
3.1 Development of antigen-displaying PHA_{MCL} beads produced in <i>P. aeruginosa</i>.....	69
3.1.1 N-terminal fusion of PopB to PhaC1 _{Pa}	70
3.1.2 C-terminal fusion of PopB to PhaC1 _{Pa}	73
3.1.3 Gene expression and PHA _{MCL} bead production.....	78
3.1.4 Characterisation of PHA _{MCL} beads displaying <i>P. aeruginosa</i> antigens.....	79
3.1.5 Display of recombinant PhaC1 _{Pa} -antigen fusion protein on the surface of PHA _{MCL} beads.....	84
3.2 Development of antigen-displaying PHA_{SCL} beads produced in <i>E. coli</i> strain ClearColi™.....	88
3.2.1 Construction of pET-14b_Ag-PhaC, pET-14b_PhaC-PopB and pET- 14b_PhaC-PopB Ag.....	89
3.2.2 Construction pET-16b_His ₁₀ -PopB Ag for the production of soluble protein.....	94
3.2.3 Gene expression and PHA _{SCL} bead production.....	96
3.2.4 Characterisation of PHA _{SCL} beads displaying <i>P. aeruginosa</i> antigens.....	97
3.2.5 Display of recombinant PhaC-antigen fusion protein on the surface of PHA _{SCL} beads.....	101
3.2.6 The protein profiles of soluble proteins His ₁₀ -Ag and His ₁₀ - PopB Ag.....	103
3.3 Immunological analysis of the PHA beads and soluble proteins.....	105
3.3.1 Vaccine formulations and mice vaccination.....	107
3.3.2 Immunological response to the antigen-displaying PHA beads.....	113
3.3.3 Challenge with <i>P. aeruginosa</i> N13 strain.....	116
3.4 Generation of the <i>cdrA</i> knockout mutant strain and characterisation..	118
3.4.1 Generation of <i>P. aeruginosa</i> PAO1 $\Delta\Delta\Delta\Delta cdrA$	120

3.4.2 Psl production of the <i>P. aeruginosa</i> PAO1 $\Delta\Delta\Delta\Delta cdrA$ mutant.....	122
Chapter 4: Discussion	124
4.1 Successful PhaC _{1Pa} -PopB bead production but unacceptable yields of PhaC _{1Pa} -PopBAG beads produced in <i>P. aeruginosa</i>	124
4.2 Successful display of PopBAG on the PHA _{SCL} bead surface at high copy number produced in <i>E. coli</i> strain ClearColi™.....	127
4.3 Mice vaccinated with PhaC-PopB and PhaC-PopBAG beads produced from <i>E. coli</i> strain ClearColi™ induced high levels of IL-17 cytokine.....	129
4.4 PhaC _{1Pa} -PopB and Ag-PhaC beads gave vaccinated mice some protection against <i>P. aeruginosa</i> infection.....	132
4.5 Creation of <i>cdrA</i> knockout mutant provides free Psl as potential novel vaccine target.....	134
4.6 Future directions.....	135
4.7 Conclusions.....	137
Appendix I: SDS-PAGE and immunoblot analysis of the whole-cell lysate and the PHA _{MCL} beads.....	139
Appendix II: Mass spectrometry (MS) analysis of PhaC _{1Pa} , PhaC _{1Pa} -fusion proteins, PhaC, PhaC-fusion proteins, and soluble proteins.....	140
Appendix III: Protein profile analysis of the whole-cell lysate and the isolated soluble proteins separated by SDS-PAGE and gel stained with Coomassie Blue.....	144
References	145

List of abbreviations

A full list of abbreviations used:

°C	Degree Celsius
APC	Antigen presenting cell
Ag	OprI, OprF and AlgE <i>P. aeruginosa</i> antigens
AGE	Agarose gel electrophoresis
Ag-PhaC	Ag-PHA _{SCL} synthase
Ag-PhaC1 _{Pa}	Ag-PHA _{MCL} synthase
Amp	Ampicillin
APS	Ammonium persulfate
BL21	<i>E. coli</i> production strain
BSA	Bovine serum albumin
Cb	Carbenicillin
CDW	Cellular dry weight
Cm	Chloramphenicol
Δ	Delta (deleted)
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
dNTPs	Deoxyribonucleotide triphosphates
ELISA	Enzyme-linked immunosorbent assay
EtOH	Ethanol
EDTA	Ethylenediaminetetraacetic acid
g	Gravity/gram
Gm	Gentamicin
GTP	Guanosine triphosphate
HCPs	Host cell proteins
HRP	Horseradish peroxidase
IgG	Immunoglobulin G
IPTG	Isopropyl β-D-1-thiogalactopyranoside
kDa	Kilo Daltons
λ	Lambda (wavelength or type of phage)
λ-DNA	Phage Lambda DNA
LacZ	β-galactosidase

LB	Luria-Bertani (broth)
L	Litre
M	Molarity
ml	Millilitre
mM	Millimolar
MOPS	Morpholinopropane sulfonic acid
MS	Mass spectrometry
OD	Optical density
PCR	Polymerase chain reaction
PhaA	β -ketothiolase
PAO1	<i>P. aeruginosa</i> production strain
PHAs	Polyhydroxyalkanoic acids
PHASCL	Short chain length PHAs
PHAMCL	Medium chain length PHAs
PhaB	Acetoacetyl-CoA reductase
PhaC	PHASCL synthase
PhaC-PopB	PHASCL synthase-PopB
PhaC-PopBAG	PHASCL synthase-PopBAG
PhaC1 _{Pa}	PHAMCL synthase
PhaC1 _{Pa} -PopB	PHAMC synthase-PopB
PhaE	Type III PHA synthase subunit
PhaP	Phasin
PhaR	Phasin regulatory protein
PHB	Poly(3-hydroxybutyric acid)
PIA	Pseudomonas isolation agar
PopBAG	Single fusion of PopB, OprI, OprF, and AlgE <i>P. aeruginosa</i> antigens
REs	Restriction endonucleases
SDS	Sodium dodecyl sulfate
SDS-PAGE	Sodium dodecyl sulfate gel electrophoresis
TBE	Tris-Borate-EDTA buffer
Tc	Tetracycline
TE	Tris-EDTA buffer

TEM	Transmission and Electron Microscopy
TEMED	Tetramethylethylenediamine
Tet	Tetracycline
TLR	Toll-like receptors
T _m	Primer melting temperature
Tris	Trishydroxymethylaminomethane
v/v	Volume per volume
w/v	Weight per volume
X-Gal	5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside
XL1-Blue	<i>E. coli</i> cloning strain

List of Figures

Figure 1	Characteristics of the two major classes of biopolyesters, PHA _{SCL} and PHA _{MCL}	3
Figure 2	Metabolic routes for PHA biosynthesis composed of short-chain length and medium-chain length 3-hydroxy fatty acids.....	7
Figure 3	Models of PHA bead formation.....	8
Figure 4	Applications of functionalized PHA beads.....	11
Figure 5	Promising vaccines' protective mechanisms against <i>P. aeruginosa</i> ..	23
Figure 6	A schematic overview of the generation of <i>P. aeruginosa</i> knockout mutant PAO1 $\Delta C\Delta 8\Delta F$	25
Figure 7	Three stages of cell culture of <i>P. aeruginosa</i> strains from frozen stock for PHA _{MCL} bead production.....	43
Figure 8	Two stages of cell culture of <i>E. coli</i> strains from frozen stock for PHA _{SCL} bead production.....	44
Figure 9	Strategy for the construction of pHERD20T-2_PopBAg-PhaC1 _{Pa}	71
Figure 10	Strategy for the construction of pHERD20T-2_PopB-PhaC1 _{Pa}	72
Figure 11	Strategy for the construction of pHERD20T-2_PhaC1 _{Pa} -PopB.....	74
Figure 12	Strategy for the construction of pHERD20T-2_Ag-PhaC1 _{Pa} -PopB..	75
Figure 13	Strategy for the construction of pHERD20T-2_PhaC1 _{Pa} -PopBAg...77	
Figure 14	Fluorescence microscopy images of whole-cells and PHA _{MCL} beads produced in recombinant <i>P. aeruginosa</i> PAO1 $\Delta C\Delta 8\Delta F$ or PAO1 $\Delta C\Delta 8\Delta F\Delta P$ harbouring various fusion protein-encoding pHERD20T-2 expression vectors stained with Nile-red.....	81
Figure 15	TEM analysis of recombinant <i>P. aeruginosa</i> harbouring various plasmids and the isolated PHA _{MCL} beads displaying <i>P. aeruginosa</i> antigens.....	82
Figure 16	GC-MS analysis of recombinant <i>P. aeruginosa</i> harbouring various plasmids and the isolated PHA _{MCL} beads displaying <i>P. aeruginosa</i> antigens.....	83
Figure 17	Protein profile analysis of whole-cell lysate and the PHA _{MCL} beads separated by SDS-PAGE and gel stained with Coomassie Blue.....	85
Figure 18	Strategy for the construction of pET-14b_Ag-PhaC for PHA _{SCL} bead production in <i>E. coli</i> strain ClearColi TM	91

Figure 19	Strategy for the construction of pET-14b_PhaC-PopB for PHA _{SCL} bead production in <i>E. coli</i> strain ClearColi™.....	92
Figure 20	Strategy for the construction of pET-14b_PhaC-PopB _{Ag} for PHA _{SCL} bead production in <i>E. coli</i> strain ClearColi™.....	93
Figure 21	Strategy for the construction of pET-16b_His ₁₀ -PopB _{Ag}	95
Figure 22	Fluorescence microscopy images of whole-cells and the isolated PHA _{SCL} beads produced in recombinant <i>E. coli</i> ClearColi™ strain, harbouring pMCS69 and various fusion protein encoding pET expression vectors stained with Nile red.....	98
Figure 23	TEM analysis of recombinant <i>E. coli</i> harbouring pMCS69 and various fusion protein encoding pET expression vectors, and the isolated PHA _{SCL} beads displaying <i>P. aeruginosa</i> antigens.....	99
Figure 24	GC-MS analysis of recombinant <i>E. coli</i> strain ClearColi™ harbouring various plasmids and of the isolated PHA _{SCL} beads displaying antigens.....	100
Figure 25	Protein profile analysis of the whole-cell lysate and the isolated PHA _{SCL} beads separated by SDS-PAGE and gel stained with Coomassie Blue.....	102
Figure 26	Protein profile analysis of the whole-cell lysate and the isolated soluble proteins separated by SDS-PAGE and gel stained with Coomassie Blue.....	104
Figure 27	A schematic representation of the plasmid constructs for the production of PHA _{MCL} beads from <i>P. aeruginosa</i> , and PHA _{SCL} beads and soluble proteins from <i>E. coli</i> strain ClearColi™ for animal testing.....	106
Figure 28	A schematic overview of the production and immunological evaluation of custom-made PHA beads displaying <i>P. aeruginosa</i> candidate antigens derived from <i>P. aeruginosa</i> and <i>E. coli</i>	110
Figure 29	IL-17 cytokine analysis from mice splenocytes stimulated with PopB/PcrH, His ₁₀ -Ag, His ₁₀ -PopB _{Ag} or PhaC beads and analysed by solid-phase sandwich ELISA.....	114
Figure 30	IgG1 and IgG2c titers expressed in EC50 values in response to PopB/PcrH, His ₁₀ -Ag and PhaC beads analysed by ELISA for each immunized group.....	115

Figure 31	Survival percentage analysis of the vaccinated mice challenged with <i>P. aeruginosa</i> N13 strain.....	117
Figure 32	Strategy for the generation of <i>cdrA</i> knockout mutant.....	119
Figure 33	Confirmation of <i>cdrA</i> deletion mutant.....	121
Figure 34	Psl production analysis of the <i>cdrA</i> knockout mutant using solid surface attachment (SSA) assay and ELISA.....	123

List of Tables

Table 1	The four classes of PHA synthases.....	5
Table 2	Promising antigens for <i>P. aeruginosa</i> vaccine.....	18
Table 3	Bacterial strains used in this study.....	30
Table 4	Plasmids used in the development of PHA _{MCL} beads displaying antigens produced from <i>P. aeruginosa</i>	32
Table 5	Plasmids used in the development of PHA _{SCL} beads displaying antigens produced from <i>E. coli</i> strain ClearColi™.....	34
Table 6	Plasmids used in the development of soluble proteins produced from <i>E. coli</i> strain ClearColi™.....	35
Table 7	Plasmids used in the development of <i>cdrA</i> knockout mutant.....	35
Table 8	Primers used in the generation PHA _{MCL} beads displaying antigens produced from <i>P. aeruginosa</i>	36
Table 9	Primers used in the generation of PHA _{SCL} beads displaying antigens produced from <i>E. coli</i> strain ClearColi™.....	37
Table 10	Primers used for generating <i>cdrA</i> knockout mutant.....	37
Table 11	Sequencing primers used in this study.....	38
Table 12	Antibiotic stocks and final concentrations.....	42
Table 13	PCR reaction mixture using Platinum® <i>Pfx</i> DNA polymerase.....	50
Table 14	PCR reaction mixture using Taq polymerase (Thermo Fisher Scientific).....	50
Table 15	PCR reaction condition.....	51
Table 16	DNA ladders: λ / <i>Pst</i> I and GeneRuler 100 bp ladder plus.....	53
Table 17	Protein marker used in SDS-PAGE.....	63
Table 18	Identification of the PHA _{MCL} bead associated host cell proteins (HCPs) by MS.....	86
Table 19	Formulation of the PHA _{MCL} beads from <i>P. aeruginosa</i> (PA).....	108
Table 20	Formulation of the PHA _{SCL} beads from <i>E. coli</i>	109
Table 21	Formulation of the soluble proteins from <i>E. coli</i>	109